Financial Data and Key Metrics Changes - Acadia Pharmaceuticals reported total revenues of $244.3 million for Q1 2025, representing a 19% increase year-over-year [6][29] - R&D expenses increased to $78.3 million from $59.7 million in Q1 2024, driven by higher spending on clinical stage programs [32] - SG&A expenses rose to $126.4 million from $108 million in Q1 2024, primarily due to ongoing consumer activation campaigns for NUPLAZID and expansion of the Debut team [32] Business Line Data and Key Metrics Changes - Debut sales reached $84.6 million in Q1 2025, an 11% increase from the previous year, with a record number of unique patients receiving shipments [7][29] - NUPLAZID generated $159.7 million in revenue for the quarter, up 23% year-over-year, with 6% of this growth attributed to volume [7][31] Market Data and Key Metrics Changes - The number of unique patients receiving Debut shipments was 954, marking an all-time high for the brand [7][11] - NUPLAZID's gross price increased by over 2% year-over-year, with a gross-to-net adjustment of 24.1% for the quarter [31] Company Strategy and Development Direction - Acadia is focused on accelerating the commercial trajectory of Debut and capitalizing on the momentum of NUPLAZID while expanding its global presence [35] - The company plans to host its first R&D Day to provide insights into its development strategy and pipeline innovations [9][35] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of Debut's growth and reiterated full-year sales guidance for both Debut and NUPLAZID [7][35] - The timeline for the COMPASS PWS Phase III study results is now expected by the end of 2025, indicating progress in pipeline development [9][35] Other Important Information - Acadia anticipates EMA approval for Debut in Q1 2026, with a substantial market opportunity in Europe for Rett syndrome patients [14][28] - The company has received orphan drug designation for trofinetide in Japan, which may lead to priority review [28] Q&A Session Summary Question: What does good 101 data look like and how does it relate to FDA discussions? - Management indicated that statistically significant results demonstrating a clinically meaningful impact on hyperphagia would be considered good data [40] Question: How should we model a European price for Debut? - Management expressed confidence in obtaining a strong EU price that reflects the value provided to patients in the Rett community [41] Question: What are the key growth drivers for NUPLAZID and Debut from Q1 to Q2? - Management highlighted patient demand and the impact of expanded customer models as key growth drivers for both brands [44][46] Question: What are the biggest risks to the approval process for trofinetide in the EU? - Management stated confidence in the EMA approval process, noting that they are on track with the regulatory timeline [80] Question: How does Acadia view its positioning against Celeno's product for Prader Willi? - Management believes there is room for multiple therapies in the Prader Willi space, emphasizing the complexity of patient needs [95]

Financial Data and Key Metrics Changes - Total revenues for Q1 2025 reached $114.8 million, a year-over-year increase of $32.9 million, translating to approximately 40% growth [11][20] - Adjusted for voluntary product withdrawals, revenues would have been $118.6 million, representing approximately 45% year-over-year growth [11][20] - Adjusted net income grew by 87% year-over-year to $33.3 million, while adjusted EBITDA increased by 81% to $47.9 million [12][22] Business Line Data and Key Metrics Changes - The increase in total revenue is primarily attributed to higher sales of Ascentive, reflecting increased acceptance and utilization by physicians, payers, and patients [20] - Gross profit for Q1 2025 was $61.1 million, with a gross margin of 53.2%, up from 47.8% in Q1 2024, driven by a favorable mix of higher margin immunoglobulin sales [21] Market Data and Key Metrics Changes - The company has seen robust demand for its commercial products, particularly Ascentive and BIVIGAM, with new patient starts continuing to grow [13][14] - Cash on hand and accounts receivable grew to a combined $171 million at the end of Q1 2025, providing a strong buffer against market volatility [14][24] Company Strategy and Development Direction - The company is focused on advancing its R&D platform and optimizing production capabilities, particularly with the recent FDA approval of the yield enhancement production process, which is expected to increase bulk immunoglobulin output by 20% [8][12] - A stock repurchase program has been authorized, allowing the company to buy back up to $500 million of its common stock, reflecting confidence in its financial position and future growth [15][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to achieve sustainable revenue and earnings growth, driven by a strong balance sheet and capital flexibility [14][26] - The company anticipates significant growth in cash flow and plans to utilize this for debt reduction, funding R&D, and stock repurchases [43][44] Other Important Information - The company has successfully navigated recent geopolitical and trade challenges due to its U.S.-based supply chain and domestic operations [7][8] - The FDA's approval of the yield enhancement process is seen as a pivotal achievement, validating the company's R&D efforts and enhancing its market position [9][10] Q&A Session Summary Question: Guidance increase and yield enhancement process - Management confirmed that three conformance lots were manufactured to secure FDA clearance, and they are conservatively excluding these from 2025 guidance [31][33] Question: Demand generation and backlog for Ascentive - Management indicated that operational expenses are expected to normalize, and demand indicators for all products are strong, supporting revenue growth [41][42] Question: Supply agreements and plasma collection - Management reported that nearly all new centers are contributing to plasma supply, exceeding initial forecasts and supporting increased guidance [49][51] Question: Health economic outcome data for Ascentive - Management is on track to publish health economic outcome data by year-end, which is expected to resonate with payers and support access to the drug [63][64] Question: Voluntary product withdrawals - Management clarified that the withdrawals were due to known adverse events and are considered a one-time occurrence, with no expected ongoing impacts [66][70] Question: Intellectual property extension - Management expressed confidence in extending the IP for Ascentive and highlighted the robust patent protection in place [72][75]

Summary of Conference Call Company Overview - The conference call was led by Andrew Yoon, director of finance and investor relations, discussing sales results for the retail month of April, comparing it to the same period last year [1] Key Financial Metrics - Net sales for April reached $21.18 billion, marking a 7% increase from $19.8 billion in the previous year [2] - The month had one less shopping day compared to last year due to the shift in Easter, negatively impacting total and comparable sales by approximately 1.5% to 2% [2] Comparable Sales Performance - Reported comparable sales for April were as follows: - US: 5.2% - Canada: 1.5% - Other International: 3.2% - Total Company: 4.4% - E-commerce: 12.6% [3] - Comparable sales excluding impacts from gasoline prices and foreign exchange were: - Total Company: 6.7% - E-commerce: 13% [3] - Comp traffic increased by 4.2% worldwide and 5% in the US [3] Impact of External Factors - Foreign currency fluctuations negatively impacted total and comparable sales: - Canada: -1.6% - Other International: -2.5% - Total Company: -0.6% [3] - Gas price deflation negatively impacted total reported comparable sales by approximately -1.7%, with the average worldwide selling price per gallon down about 13.4% year-over-year [4] Regional Performance - Strongest comparable sales in the US were observed in the Midwest, Northeast, and Southeast regions [5] - Internationally, the best results were seen in Mexico, Korea, and Taiwan [5] Merchandise Highlights - Foods and sundries showed positive high single-digit growth [5] - Better performing departments included: - Fresh foods: high single digits - Meat and bakery: strong performance - Non-foods: mid to high single digits, with jewelry, majors, and home furnishings performing well [6] - Ancillary business sales were down mid to high single digits, while pharmacy, optical, and food court were the top performers [7] Future Outlook - The May reporting period will cover the four weeks beginning May 5 and ending June 1, compared to the same period last year [7]

EARNINGS PRESENTATION FIRST QUARTER 2025 May 7, 2025 LEGAL DISCLAIMERS Forward-Looking Information This presentation includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Alta's actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," " ...

Prime Rib Steak Sandwich Cautionary Statements Forward-Looking Statements ir addition to historial informasion, this presentation and our reaming conference call contain forwards of Second 274ct the Securities Accolor 1933, someroled, Section 2D the Phouse Securities Libgulion Reform Ast of 1995. Forward dobling caternents, written, pal o o chience, real o c orbrewise note, represent the Cornçary sy supection of ot "fin\"," "Mould," "seds," "neerlot," "port"," sornes," "pola" "sechnoras," "poices: "or "nici ...

Q1 2025 Q1 2025 Financial Highlights Q1 2025 Q1 2024 Revenue $24.4 million $30.7 million Adj. EBITDA1 $5.7 million $12.5 million Total Certs 27,638 28,189 (1) See reconciliation of GAAP to non-GAAP financial measures on page 5 2 23, 159, 221 149, 201, 61 20, 83, 150 Earnings Supplement 3, 102, 170 146, 192, 219 166, 166, 166 Key Performance Indicators | | | | Three Months Ended March 31, | | | --- | --- | --- | --- | --- | | | | 2025 | | 2024 | | Certs | | | | | | Credit Union & Bank | | 24,215 | | 21,078 | ...

Investor Strategic Update 2025 As of May 7, 2025 Forward Looking Statements This presentation contains certain forward-looking statements within the meaning of the federal securities laws, including statements about the outlook of our business and industry and other matters referenced in our earnings release and SEC filings. All statements other than statements of historical fact contained in this presentation, including statements on our business strategy, plans, objectives, financial results, operating re ...

H&R BLOCK Q3 FY25 Financial Results Conference Call Q3 FY25 Financial Results Conference Call May 7, 2025 H&R BLOCK Q3 FY25 Financial Results Conference Call Jordyn Eskijian Program Manager, Investor Relations & ESG H&R BLOCK Q3 FY25 Financial Results Conference Call Safe Harbor Statement Forward-Looking Statement This presentation contains forward-looking statements within the meaning of the securities laws. Forward-looking statements can be identified by the fact that they do not relate strictly to histor ...

BLUE BIRD CORPORATION (NASDAQ: BLBD) FY2025 Second Quarter Results 2 Important Disclaimers Forward Looking Statements Earnings Conference Call May 7, 2025 Agenda | Introductions & | Mark Benfield | | --- | --- | | Forward-Looking Statements | Executive Director, Investor Relations | | Key Results and Highlights | John Wyskiel | | | President & CEO | | Financial Results | Razvan Radulescu | | | CFO | | Outlook | John Wyskiel | | | President & CEO | | Q&A | Group | This presentation includes forward-looking s ...

| . | | --- | | and the country of the same of the county of the county of the county of | | GREASURED FOR THE OF OF EN INFORMATION OF IN AT IN OIL OF CHILDIN . . . | | . . ADDRESSES OF IS IN 30 SEPRANAGEMENT OF IN TO SUSPER | | . | | and the control of the control of the control of the first of the firs | | . | Q1 2025 Financial Results May 7, 2025 Safe Harbor Statement Information, statements and projections contained in these presentation slides and related conference call concerning Fortinet's business ...